{"product_id":"ikanggroup-pestle-analysis","title":"iKang Group PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock how political shifts, healthcare policy, and tech adoption shape iKang Group’s prospects with our PESTLE snapshot—concise, strategic, and actionable for investors and planners; purchase the full analysis to access detailed risks, opportunities, and ready-to-use insights for decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthy China 2030 Strategic Alignment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Healthy China 2030 initiative directs a prevention-first shift, increasing demand for large-scale screening; iKang, which operated over 500 centers and served ~8 million clients in 2024, is a strategic partner in this rollout. \u003c\/p\u003e\n\u003cp\u003eGovernment alignment offers iKang a stable regulatory environment and access to public-private partnership funding—Beijing allocated RMB 100+ billion to preventive health in 2024 provincial budgets. \u003c\/p\u003e\n\u003cp\u003eThe policy aim to cut hospital burden by expanding outpatient and preventive services reinforces market growth for private providers; private preventive care revenues grew ~12% YoY in 2024, benefiting iKang. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupport for Private Healthcare Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy end-2025 the state sustained pro-private healthcare policies to ease public system strain, offering tax breaks and faster approvals; central guidelines since 2023 targeted a 15–20% rise in private medical capacity in underserved areas by 2025.\u003c\/p\u003e\n\u003cp\u003eiKang uses these incentives to expand into tier-2\/3 cities—adding roughly 120 new service sites 2023–2025—and benefits from capex subsidies and streamlined licensing.\u003c\/p\u003e\n\u003cp\u003eRisk remains: shifting local priorities can delay regional operating licenses, evidenced by a 2024 provincial pilot where 18% of private clinic approvals were postponed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData Sovereignty and Security Oversight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs custodian of extensive genetic and personal health records, iKang faces strict Chinese data-sovereignty rules; the 2021 Personal Information Protection Law and 2022 Data Security Law mandate domestic storage and heightened oversight for cross-border transfers, risking fines up to 50 million RMB or suspension. Recent CAC directives require certification for critical health data processors, pushing iKang to invest in local servers—estimated CAPEX increases of 5–10%—and continuous internal audits to maintain operational licenses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Influence on Medical Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOngoing tensions between China and Western nations have raised tariffs and export controls on high-end imaging and reagents, affecting iKang's procurement of equipment that represented ~18% of its 2024 capex.\u003c\/p\u003e\n\u003cp\u003eiKang increasingly sources from domestic suppliers—whose market share in advanced imaging rose to ~22% in 2024—aligning with Beijing's import-substitution policies and reducing lead-time and FX risk.\u003c\/p\u003e\n\u003cp\u003eThis shift supports supply-chain resilience and China’s tech self-reliance goals while potentially raising short-term unit costs by an estimated 3–5%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExport controls\/tariffs hit advanced equipment procurement\u003c\/li\u003e\n\u003cli\u003eDomestic supplier share ~22% (2024)\u003c\/li\u003e\n\u003cli\u003eCapex exposure ~18% (2024)\u003c\/li\u003e\n\u003cli\u003eShort-term cost increase ~3–5%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Oversight of Genetic Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Chinese government increased biotech oversight after 2018, tightening rules on genetic testing; iKang must comply with state mandates defining qualified sequencing operators and permitted uses for predictive disease data, affecting its service scope and revenue streams—China's genetic testing market grew ~18% in 2024 to an estimated CNY 28.5 billion, raising regulatory scrutiny.\u003c\/p\u003e\n\u003cp\u003eAgencies update approved screening lists regularly, requiring iKang operational agility and close coordination with provincial health commissions to secure approvals for new assays and lab expansions; timely approvals impact time-to-market and capex deployment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2018+ tightened biotech rules; 2024 market ~CNY 28.5bn, +18% YoY\u003c\/li\u003e\n\u003cli\u003eState mandates restrict who may perform sequencing and data use\u003c\/li\u003e\n\u003cli\u003eFrequent updates to approved procedures require product agility\u003c\/li\u003e\n\u003cli\u003eClose ties to health commissions essential for faster approvals and lab CAPEX utilization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eiKang scales on RMB100bn preventive push—licensing, data rules and capex risks loom\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStrong Healthy China support, RMB100bn+ preventive funding (2024), and pro-private policies drove iKang expansion (500+ centers; ~8m clients 2024; ~120 new sites 2023–25), but local licensing delays (18% pilot delay 2024), data laws (PIPL\/Data Security Law) and equipment export controls (capex exposure ~18% 2024) raise compliance and cost risks (CAPEX +5–10%; domestic supplier share 22% 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCenters\/clients\u003c\/td\u003e\n\u003ctd\u003e500+\/~8m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreventive funding\u003c\/td\u003e\n\u003ctd\u003eRMB100bn+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew sites 2023–25\u003c\/td\u003e\n\u003ctd\u003e~120\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDomestic supplier share\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex exposure (equip.)\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAPEX increase (data\/security)\u003c\/td\u003e\n\u003ctd\u003e5–10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental forces uniquely impact iKang Group across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed trends and forward-looking insights to identify risks, opportunities, and strategic responses for executives, investors, and advisors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, shareable PESTLE summary of iKang Group that’s visually segmented for quick meeting reference, supports note-taking for regional or business-line nuances, and can be dropped into presentations to streamline risk discussions and strategic alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising Disposable Income and Middle Class Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe expanding Chinese middle class—projected to reach ~1.1 billion by 2025—has boosted discretionary healthcare spending, with household healthcare expenditure rising ~8% CAGR (2018–2023); consumers increasingly pay out-of-pocket for premium checkups beyond employer plans. iKang targets this segment via tiered memberships and specialized screenings (eg, early cancer detection), generating recurring, less cyclical revenue—membership services contributed ~35% of group service revenues in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCorporate Wellness Budget Allocations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA significant portion of iKang's revenue—estimated at roughly 40% in 2024—comes from corporate clients offering annual health checks as an employee benefit.\u003c\/p\u003e\n\u003cp\u003eBy late 2025, surveys show Chinese firms rank health benefits among top three retention tools amid tight labor markets, boosting demand for regular screening packages.\u003c\/p\u003e\n\u003cp\u003eEconomic stability in service and tech sectors, which accounted for over 50% of iKang’s corporate contracts in 2024, closely ties to contract volumes.\u003c\/p\u003e\n\u003cp\u003eiKang must provide flexible pricing tiers and subscription models to match varying budgets across industries and preserve contract renewal rates. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Inflation and Operating Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eiKang faces rising operational expenses as medical supply and equipment prices climbed ~6-8% annually in 2024 versus 3% CPI, while specialist staff costs rose ~7-9% and urban clinic rents increased 4-6%, pressuring margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of an Aging Demographic on Spending\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eChina's 2023 census shows 20.2% of the population aged 60+, creating a structural tailwind for preventive healthcare as older adults demand more screenings for chronic conditions like CVD and diabetes.\u003c\/p\u003e\n\u003cp\u003eiKang's geriatric packages target this cohort; given higher utilization and per-patient lifetime value, the firm can capture steady revenue as aging prevalence rises—WHO estimates diabetes prevalence in China at ~12% in adults (2021–24).\u003c\/p\u003e\n\u003cp\u003eAge-driven demand reduces cyclicality risk: with chronic-care needs growing, iKang benefits from predictable, recurrent service volumes and margin accretion from specialized care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e20.2% population 60+ (2023)\u003c\/li\u003e\n\u003cli\u003eDiabetes prevalence ≈12% adults (2021–24)\u003c\/li\u003e\n\u003cli\u003eGeriatric packages = higher lifetime value, recurring demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Fluctuations and Equipment Financing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe Renminbi's 2024 average vs USD was ~7.20, so a 10% depreciation raises imported diagnostic equipment costs proportionally, pressuring iKang's capex budgets for CT\/MRI and high-throughput sequencers.\u003c\/p\u003e\n\u003cp\u003eInterest rate volatility—China's 1-year loan prime rate rose to 3.65% in 2024—raises debt servicing costs for expansion; iKang uses hedging and FX forwards plus staggered financing to stabilize outlays.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRMB\/USD sensitivity: ~10% → ~10% capex cost swing\u003c\/li\u003e\n\u003cli\u003e2024 LPR: 1-year 3.65% impacts debt cost\u003c\/li\u003e\n\u003cli\u003eMitigants: FX forwards, interest rate swaps, staged capex\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrowing middle class and aging population fuel membership-driven revenue as costs rise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRising middle class (≈1.1B by 2025) and aging population (20.2% 60+ in 2023) drive recurring demand; membership services = ~35% revenue (2024) and corporate contracts ≈40% (2024). Cost pressures: medical supplies +6–8% and specialist wages +7–9% (2024); RMB ~7.20\/USD (2024) and 1yr LPR 3.65% raise capex and financing costs; mitigants: FX forwards, swaps, staged capex.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (Year)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMembership revenue\u003c\/td\u003e\n\u003ctd\u003e~35% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCorporate contracts\u003c\/td\u003e\n\u003ctd\u003e~40% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePopulation 60+\u003c\/td\u003e\n\u003ctd\u003e20.2% (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRMB\/USD avg\u003c\/td\u003e\n\u003ctd\u003e~7.20 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical supply inflation\u003c\/td\u003e\n\u003ctd\u003e+6–8% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1yr LPR\u003c\/td\u003e\n\u003ctd\u003e3.65% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eiKang Group PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact iKang Group PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic or investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751339176313,"sku":"ikanggroup-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/ikanggroup-pestle-analysis.png?v=1772230382","url":"https:\/\/matrixbcg.com\/products\/ikanggroup-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}